Articles related to IMMUNOTHERAPY

The meta-analysis included data from nearly 13,000 patients across 30 published trials. Grade 3 or 4 AEs occurred in nearly 70% of patents receiving TKIs compared with 37% for those receiving ICIs.

When immune checkpoint inhibitor therapy was started, detectable levels of acetaminophen in the plasma were linked to significantly poorer PFS and OS. The fact that poorer clinical outcomes were demonstrated to be unrelated to other prognostic variables, such as age, performance status, the quantity of past lines of therapy, and tumor kind, is noteworthy.

Results from the phase 1b CodeBreak 100/1 trial show that administering the novel KRASinhibitor sotorasib alone prior to combining it with an immune checkpoint inhibitor led tolower rates of grade 3-4 treatment-related adverse events compared with beginningadministration of the treatments concurrently.

At 12 months, nivolumab plus chemotherapy yielded a PFS of 89.3% versus 60.7% forchemotherapy alone and an OS of 98.2% compared with 82.1%, respectively. Thecombination improved median PFS by 52% compared with chemotherapy alone at amedian follow-up of 26.1 months. (See also NADIM II and IMpower010 Provide Support for Neoadjuvant and Adjuvant Immunotherapy in Lung Cancer)

An epigenetic inhibitor can boost immune system activity in patients with ovarian cancer, according to a Northwestern Medicine study published in the Journal of Clinical Investigation.

This interview reviews the implications of three recent studies — KEYNOTE-158, EMPOWER, KEYNOTE-826 — on immunotherapy in cervical cancer. In addition to the compelling connection between cervical cancer and the immune system, and therefore the interest in immunotherapy for cervical cancer, immunotherapy offers some key advantages over chemotherapy in this setting. It benefits patients with previous radiation as much as it benefits patients who are radiotherapy-naïve and it is less associated with the formation of fistulas than chemotherapy.